Financials data is unavailable for this security.
View more
Year on year AIM ImmunoTech Inc had net income fall 48.94% from a loss of 19.45m to a larger loss of 28.96m despite a 43.26% increase in revenues from 141.00k to 202.00k. An increase in the selling, general and administrative costs as a percentage of sales from 9,272.34% to 10,710.40% was a component in the falling net income despite rising revenues.
| Gross margin | 71.14% |
|---|---|
| Net profit margin | -13,952.74% |
| Operating margin | -15,715.92% |
| Return on assets | -113.70% |
|---|---|
| Return on equity | -157.79% |
| Return on investment | -149.16% |
More ▼
Cash flow in USDView more
In 2023, cash reserves at AIM ImmunoTech Inc fell by 21.61m. Cash Flow from Financing totalled 485.00k or 240.10% of revenues. In addition the company used 21.27m for operations while cash used for investing totalled 832.00k.
| Cash flow per share | -0.5568 |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | 0.1068 |
|---|---|
| Tangible book value per share | 0.0632 |
More ▼
Balance sheet in USDView more
| Current ratio | 1.17 |
|---|---|
| Quick ratio | -- |
| Total debt/total equity | 0.4322 |
|---|---|
| Total debt/total capital | 0.3018 |
More ▼
